Received: 16 January 2019
Accepted: 26 April 2019
First Online: 17 May 2019
Ethics approval and consent to participate
: All the participants gave written informed consent and the study design and procedures, outlined in detail elsewhere [CitationRef removed], were granted approval by local ethics committees (Germany: Universitat Ulm Ethikkommission [312/08]. Italy: Comitato Etico Provinciale Treviso [XLIV-RSA/AULSS7]. The Netherlands: Medisch Ethische Toetsingscommissie Vrije Universiteit Amsterdam [2002/141]. Spain: Comité Ético de Investigación Clínica del Hospital Universitario La Paz Madrid [PI-1080]. Sweden: Till forskningsetikkommittén vid Karolinska Instituted Stockholm [00–132]. UK: Hertfordshire Research Ethics Committee [10/H0311/59]).
: Not applicable.
: CC: consultancy, lecture fees and honoraria from Alliance for Better Bone Health, Amgen, Eli Lilly, GSK, Medtronic, Merck, Novartis, Pfizer, Roche, Servier, Takeda, and UCB (less than $ 10,000 each).ED: speaking fees from Eli Lilly (less than $ 10,000).No competing interests were reported by the other authors.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.